• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Arcellx Inc.

    1/2/26 4:16:44 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACLX alert in real time by email
    S-8 1 d75969ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on January 2, 2026

    Registration No. 333-    

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ARCELLX, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-2855917

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    800 Bridge Parkway

    Redwood City, CA 94065

    (240) 327-0630

    (Address of principal executive offices, including zip code)

     

     

    2022 Equity Incentive Plan

    2022 Employee Stock Purchase Plan

    (Full title of the plan)

    Rami Elghandour

    President, Chief Executive Officer and Chairman of the Board of Directors

    Arcellx, Inc.

    800 Bridge Parkway

    Redwood City, CA 94065

    (240) 327-0630

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Dan Koeppen

    Robert L. Wernli Jr.

    Jennifer Fang

    Wilson Sonsini Goodrich & Rosati, P.C.

    31 West 52nd Street

    5th Floor

    New York, New York 10019

    (212) 999-5800

     

    Maryam Abdul-Kareem

    General Counsel

    Arcellx, Inc.

    800 Bridge Parkway

    Redwood City, CA 94065

    (240) 327-0630

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    Arcellx, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (i) 2,895,867 additional shares of common stock under the Registrant’s 2022 Equity Incentive Plan (the “2022 Plan”), pursuant to the provision of the 2022 Plan providing for such automatic increase in the number of shares reserved for issuance, and (ii) 312,500 additional shares of common stock under the Registrant’s 2022 Employee Stock Purchase Plan (the “2022 ESPP”), pursuant to the provision of the 2022 ESPP providing for such automatic increase in the number of shares reserved for issuance.

    Accordingly, contents of (i) the previous Registration Statement on Form S-8 filed by the Registrant with the Commission on February 7, 2022 (File No. 333-262571) (the “2022 Form S-8”), (ii) the previous Registration Statement on Form S-8 filed by the Registrant with the Commission on January 3, 2023 (File No. 333-269105) (the “2023 Form S-8”), (iii) the previous Registration Statement on Form S-8 filed by the Registrant with the Commission on January 2, 2024 (File No. 333-276346) (the “2024 Form S-8”), and (iv) the previous Registration Statement on Form S-8 filed by the Registrant with the Commission on January 6, 2025 (File No. 333-284136) (the “2025 Form S-8”, and together with the 2022 Form S-8, 2023 Form S-8 and 2024 Form S-8, the “Previous Forms S-8”), including the information incorporated by reference therein and the periodic reports filed after the Previous Forms S-8 to maintain current information about the Registrant, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8 (the “Registration Statement”).

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

     

      (1)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025;

     

      (2)

    All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (1) above; and

     

      (3)

    The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on February 1, 2022 pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by


    reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 8. Exhibits.

     

    Exhibit
    Number

      

    Exhibit Description

       Form      File
    Number
         Exhibit
    Number
         Filing
    Date
         Filed
    Herewith
     
      4.1    Specimen Common Stock Certificate      S-1/A        333-262191        4.2        1/31/22     
      5.1    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation                  X  
     23.1    Consent of Independent Registered Public Accounting Firm                  X  
     23.2    Consent of Independent Registered Public Accounting Firm                  X  
     23.3    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)                  X  
     24.1    Power of Attorney – Arcellx, Inc. Directors                  X  
     99.1    2022 Equity Incentive Plan and forms of agreements thereunder      S-1/A        333-262191        10.3        1/31/22     
     99.2    Amended and Restated 2022 Employee Stock Purchase Plan      10-Q        001-41259        10.1        11/14/22     
    107.1    Filing Fee Table                  X  


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, California, on January 2, 2026.

     

    ARCELLX, INC.
    By:   /s/ Rami Elghandour
      Rami Elghandour
      President, Chief Executive Officer and Chairman

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Rami Elghandour

    Rami Elghandour

      

    President, Chief Executive Officer and Chairman

    (Principal Executive Officer)

      January 2, 2026

    /s/ Michelle Gilson

    Michelle Gilson

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      January 2, 2026

    *

    Ali Behbahani

       Director   January 2, 2026

    *

    Jill Carroll

       Director   January 2, 2026

    *

    David Lubner

       Director   January 2, 2026

    *

    Kavita Patel

       Director   January 2, 2026

    *

    Olivia Ware

       Director   January 2, 2026

    *

    Kristin Myers

       Director   January 2, 2026

    *

    Andrew Galligan

       Director   January 2, 2026

     

    *By:   /s/ Maryam Abdul-Kareem
    Maryam Abdul-Kareem
    Attorney-in-Fact
    Get the next $ACLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLX

    DatePrice TargetRatingAnalyst
    1/7/2026$100.00Buy
    UBS
    12/22/2025$100.00Overweight
    Wells Fargo
    11/18/2025Peer Perform
    Wolfe Research
    10/16/2025$129.00Buy
    Stifel
    6/17/2025$110.00Buy
    Citigroup
    10/8/2024$109.00Buy
    Redburn Atlantic
    9/3/2024Overweight
    Cantor Fitzgerald
    5/31/2024$70.00Overweight
    Piper Sandler
    More analyst ratings

    $ACLX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcellx Inc.

    SCHEDULE 13G/A - Arcellx, Inc. (0001786205) (Subject)

    2/5/26 1:16:32 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Arcellx Inc.

    144 - Arcellx, Inc. (0001786205) (Subject)

    1/20/26 4:27:55 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Arcellx Inc.

    S-8 - Arcellx, Inc. (0001786205) (Filer)

    1/2/26 4:16:44 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ACLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ACLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder

    -- CAR constructs representative of anito-cel (D-Domain), cilta-cel (dual VHH), and ide-cel (scFv) were assessed preclinically for tonic signaling and off-target Claudin binding -- -- No tonic signaling or off-target activity was observed with the D-Domain, supporting its unique target-specific binding profile and anito-cel's potentially best-in-class safety profile -- -- Specific off-target activity against Claudin-9 was observed with the dual VHH binder, consistent with cilta-cel's publicly available regulatory assessment reports; the D-Domain and scFv binders did not demonstrate off-target activity -- -- CAR T activation and cytokine release were observed for dual VHH and scFv bind

    2/4/26 9:00:00 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

    -- The D-Domain binder has a fast off-rate and contributes to anito-cel's differentiated pharmacology profile in multiple myeloma -- -- A simulation model of CAR T use ahead of bispecific antibodies in 4L+ RRMM is estimated to reduce the risk of progression or death by 64% and death by 48% over five years versus the reverse sequence, supporting CAR T before bispecific antibody as the sequence that delivers superior improved long-term outcomes in 4L+ RRMM -- -- Geographic inequities persist in CAR T access for MM patients marked by long travel, out-of-state care, and bypassed ATCs, highlighting systemic referral gaps and the need for ATC expansion to improve equitable access -- Arcellx

    1/21/26 4:00:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

    -- Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time -- -- Overall MRD negativity was 95% and sustained MRD negativity for >6 months was 83%, both at 10-5 sensitivity level -- -- 12-month PFS and OS rates were 82.1% and 94.0%; 18-month PFS and OS rates were 67.4% and 88.0%; 24-month PFS and OS rates were 61.7% and 83.0% -- -- To date, no delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, no Guillain-Barré syndrome, and no immune effector cell-associated enterocolitis have been observed with anito-cel to date; all patients were dosed at least 12 months ago -- -- The company re

    12/6/25 2:00:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Arcellx with a new price target

    UBS resumed coverage of Arcellx with a rating of Buy and set a new price target of $100.00

    1/7/26 9:34:38 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wells Fargo initiated coverage on Arcellx with a new price target

    Wells Fargo initiated coverage of Arcellx with a rating of Overweight and set a new price target of $100.00

    12/22/25 8:37:37 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Arcellx

    Wolfe Research initiated coverage of Arcellx with a rating of Peer Perform

    11/18/25 8:20:01 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lubner David Charles exercised 6,000 shares at a strike of $6.28 and sold $450,000 worth of shares (6,000 units at $75.00) (SEC Form 4)

    4 - Arcellx, Inc. (0001786205) (Issuer)

    1/20/26 7:59:40 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF MEDICAL OFFICER Heery Christopher converted options into 13,064 shares and sold $402,997 worth of shares (5,882 units at $68.51), decreasing direct ownership by 21% to 23,749 units (SEC Form 4)

    4 - Arcellx, Inc. (0001786205) (Issuer)

    1/14/26 7:38:10 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF MEDICAL OFFICER Heery Christopher converted options into 16,520 shares and sold $487,213 worth of shares (7,437 units at $65.51), increasing direct ownership by 118% to 29,631 units (SEC Form 4)

    4 - Arcellx, Inc. (0001786205) (Issuer)

    1/13/26 9:20:02 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arcellx Inc.

    SC 13G - Arcellx, Inc. (0001786205) (Subject)

    11/22/24 4:12:28 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

    SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

    11/14/24 4:35:36 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

    SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

    11/14/24 4:31:50 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Financials

    Live finance-specific insights

    View All

    Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

    -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. --   -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma --  -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx

    12/9/22 8:15:00 AM ET
    $ACLX
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Leadership Updates

    Live Leadership Updates

    View All

    Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

    -- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market

    3/20/25 4:00:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

    REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters. 

    6/21/22 4:05:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcellx Appoints Michelle Gilson as Chief Financial Officer

    FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.

    5/23/22 4:05:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care